High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

BACKGROUND/AIMS: Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellicelli, Adriano, Messina, Vincenzo, Giannelli, Valerio, Distefano, Marco, Palitti, Valeria Pace, Vignally, Pascal, Tarquini, Pierluigi, Izzi, Antonio, Moretti, Alessandra, Babudieri, Sergio, Dell’Isola, Serena, Marignani, Massimo, Scifo, Gaetano, Iovinella, Vincenzo, Cariti, Giuseppe, Pompili, Maurizio, Candilo, Francesco Di, Fontanella, Luca, Ettorre, Giuseppe M., Vennarecci, Giovanni, Ippolito, Antonio Massimo, Barbarini, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234881/
https://www.ncbi.nlm.nih.gov/pubmed/30970444
http://dx.doi.org/10.5009/gnl18269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234881/
https://www.ncbi.nlm.nih.gov/pubmed/30970444
http://dx.doi.org/10.5009/gnl18269

Ejemplares similares